Trials / Completed
CompletedNCT00564902
The Zeaxanthin and Visual Function Study
Randomized, Double Blind, Lutein Controlled Study of Zeaxanthin and Visual Function in Atrophic Age Related Macular Degeneration Patients
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Chrysantis, Inc. · Industry
- Sex
- All
- Age
- 45 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate if supplementation of zeaxanthin (with or without Lutein) is beneficial to patients with early and moderate Atrophic Age Related Macular Degeneration.
Detailed description
To evaluate whether or not zeaxanthin supplementation raises macular pigment optical density (MPOD). Previous research has shown MPOD to mirror visual benefits for patients with age related atrophic macular degeneration (AMD) having visual symptoms (decreased visual acuity, contrast sensitivity, photostress glare recovery and National Eye Institute Visual Function Questionnaire 25 scores), but lower risk National Eye Institute (NEI) / Age Related Eye Disease Study (AREDS) characteristics.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 3R 3'R Zeaxanthin | 8 mg per day during 12 months |
| DIETARY_SUPPLEMENT | Lutein | 9 mg of Lutein during 12 months |
| DIETARY_SUPPLEMENT | Lutein and Zeaxanthin | 8 mg of lutein and 8 mg of Zeaxanthin administered during 12 months |
Timeline
- Start date
- 2007-11-01
- Primary completion
- 2009-05-01
- Completion
- 2009-06-01
- First posted
- 2007-11-29
- Last updated
- 2012-03-29
- Results posted
- 2012-03-29
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00564902. Inclusion in this directory is not an endorsement.